Drug Profile
BMS 919373
Alternative Names: BMS-919373; Ikur inhibitor - Bristol-Myers SquibbLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antiarrhythmics; Pyridines; Quinazolines; Small molecules; Sulfonamides
- Mechanism of Action Kv1.5 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes; Atrial fibrillation; Paroxysmal atrial fibrillation
Most Recent Events
- 07 Mar 2017 Chemical structure information added
- 14 Feb 2017 Bristol-Myers Squibb terminates a phase I trial in Atrial fibrillation in USA and Canada due to insufficient enrolment(NCT02153437)
- 01 Jan 2017 Discontinued - Phase-I for Acute coronary syndromes (In volunteers) in USA (PO, Suspension)